Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.
Aiming to develop a vaccine candidate against human adenovirus-55 (HAdV-55) infections, researchers from the First Affiliated Hospital of Guangzhou Medical University (China) and collaborators have generated a replication-incompetent rAd55-5E4.
CSN5, a key COP9 signalosome subunit, regulates protein stability in the cell cycle, apoptosis and DNA repair. Its overexpression in cancer promotes tumor growth, metastasis and therapy resistance, making it a potential therapeutic target.
The signaling axis orchestrated by OX40L-OX40 is a T-cell costimulatory pathway implicated in multiple autoimmune diseases, such as atopic dermatitis (AD). Antibodies targeting this pathway have proven useful at treating AD in the clinical setting. Earendil Labs recently presented data regarding HXN-1021, an anti-OX40L antibody with potent activity and extended half-life, in vivo.
In Duchenne muscular dystrophy (DMD), deficiency of dystrophin leads to cardiomyocyte membrane instability, abnormal calcium influx, and progressive fibrotic remodeling of cardiac tissue. Histone deacetylase 6 (HDAC6) contributes to disease progression by regulating cytoskeletal dynamics and proteostasis in dystrophic muscle cells. Consequently, inhibition of HDAC6 represents a potential therapeutic strategy for addressing both the skeletal and cardiac manifestations of DMD.
C-Further, an international consortium supporting new therapeutics for pediatric cancers, has unveiled the first early-stage therapeutic programs in its pipeline. The company said it is advancing CF-012 and CF-033 through its collaborative model.
The exact genetic and epigenetic cause of the sporadic form of amyotrophic lateral sclerosis (ALS), which affects approximately 90% of patients, are largely unknown. Previous work found that mitochondrial dysfunction and metabolic dysregulation are crucial to ALS pathophysiology.
Similarities among three pediatric brain tumors that arise in different structures of the CNS – pineoblastoma, retinoblastoma and Group 3 medulloblastoma – have been linked to their shared origin during pineal gland development. Scientists at St. Jude Children’s Research Hospital have identified the molecular signatures that drive these tumors from pinealocyte progenitor cells that conserve a common differentiation program, providing a shared therapeutic target for these three cancer types.
Scientists from Fu Wai Hospital of the Chinese Academy of Medical Sciences and Shenzhen Bay Laboratory have divulged cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) inhibitors. They are reported to be useful for the treatment of autoimmune diseases, cancer, neurological disorder, diabetes, inflammatory bowel disease, pulmonary fibrosis, psoriasis and arthritis, among others.
Shanghai Deep Potential Technology Co. Ltd. has discovered serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer.
RSS
